US FDA extends review of AstraZeneca thyroid cancer drug
This article was originally published in Scrip
Executive Summary
The US FDA has extended its review by three months for AstraZeneca's experimental multitargeted kinase inhibitor, vandetanib, which the firm is seeking to market as a treatment for patients with non-operable locally advanced or metastatic medullary thyroid cancer (MTC).